RT Journal Article
SR Electronic
T1 Disease-specific contribution of pulvinar dysfunction to impaired emotion recognition in schizophrenia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.21.21257528
DO 10.1101/2021.05.21.21257528
A1 Antígona Martínez
A1 Russell H. Tobe
A1 Pablo A. Gaspar
A1 Daniel Malinsky
A1 Elisa C. Dias
A1 Pejman Sehatpour
A1 Peter Lakatos
A1 Gaurav H. Patel
A1 Gail Silipo
A1 Daniel C. Javitt
YR 2021
UL http://medrxiv.org/content/early/2021/05/23/2021.05.21.21257528.abstract
AB One important aspect for managing social interactions is the ability to rapidly and accurately perceive and respond to facial expressions, which is highly dependent upon intact processing within both cortical and subcortical components of the early visual pathways. Social cognitive deficits, including face emotion recognition (FER) deficits, are characteristic of several neuropsychiatric disorders, including schizophrenia (Sz) and autism spectrum disorders (ASD). Here, we investigated potential visual sensory contributions to FER deficits in Sz (n=28) and adult ASD (n=20) participants compared to neurotypical (n=30) controls using task-based fMRI during an implicit static/dynamic FER task. Compared to neurotypical controls, both Sz and ASD participants had significantly lower FER scores which interrelated with diminished activation of the superior temporal sulcus (STS). In Sz, STS deficits were predicted by reduced activation of both early visual regions and the pulvinar nucleus of the thalamus, along with impaired cortico-pulvinar interaction. By contrast, ASD participants showed patterns of increased early visual cortical and pulvinar activation. Large effect-size structural and histological abnormalities of pulvinar have previously been documented in Sz. Moreover, we have recently demonstrated impaired pulvinar activation to simple visual stimuli in Sz. Here, we provide the first demonstration of a disease-specific contribution of impaired pulvinar activation to social cognitive impairment in Sz.Competing Interest StatementDCJ: Intellectual property for NMDAR agonists in schizophrenia, NMDAR antagonist in depression, fMRI for prediction of ECT response and System for diagnosis of mental disorders. Equity in Glytech, AASI and NeuroRx. Scientific advisory board NeuroRx, Promentis. Consultant payments Concert, Lundbeck, Phytec, Autifony, SK LifeFunding StatementThis work was supported by NIMH grant MH49334 (DCJ).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The investigation was approved by the Nathan Kline Institute (NKI) institutional review board. Informed consent was obtained from all participants.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author (AM). The data are not publicly available due to their containing information that could compromise the privacy of research participants.